PE20091078A1 - INJECTABLE FORMULATION FOR OCRELIZUMAB (2H7) - Google Patents

INJECTABLE FORMULATION FOR OCRELIZUMAB (2H7)

Info

Publication number
PE20091078A1
PE20091078A1 PE2008001653A PE2008001653A PE20091078A1 PE 20091078 A1 PE20091078 A1 PE 20091078A1 PE 2008001653 A PE2008001653 A PE 2008001653A PE 2008001653 A PE2008001653 A PE 2008001653A PE 20091078 A1 PE20091078 A1 PE 20091078A1
Authority
PE
Peru
Prior art keywords
antibody
seq
injectable formulation
ocrelizumab
full length
Prior art date
Application number
PE2008001653A
Other languages
Spanish (es)
Inventor
David Robert Close
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20091078A1 publication Critical patent/PE20091078A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UN ANTICUERPO DE CD20 HUMANIZADO, QUIMERICO O HUMANO, DONDE EL ANTICUERPO HUMANIZADO SE SELECCIONA DEL GRUPO FORMADO POR LAS VARIANTES 2H7 A, B E I QUE CONTIENEN UNA CADENA L DE LONGITUD COMPLETA DE SEQ ID NO: 6 Y UNA CADENA LARGA DE LONGITUD COMPLETA DE SEQ ID NO: 7, 8 Y 15, O UN FRAGMENTO DE LAS MISMAS; EL ANTICUERPO QUIMERICO ES RITUXIMAB. TAMBIEN ESTA REFERIDA A UNA COMBINACION DEL ANTICUERPO CD20 CON UN FARMACO TAL COMO ETANERCEPT, INFLIXIMAB, METOTREXATO, OFATUMUMAB, CICLOFOSFAMIDA, ENTRE OTROS Y A UNA FORMULACION INYECTABLE. DICHOS ANTICUERPOS SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES, INCLUIDA LA ARTRITIS REUMATOIDEREFERRING TO A HUMANIZED, CHIMERIC OR HUMAN CD20 ANTIBODY, WHERE THE HUMANIZED ANTIBODY IS SELECTED FROM THE GROUP FORMED BY THE 2H7 A VARIANTS, BEI THAT CONTAIN A FULL LENGTH CHAIN OF SEQ ID NO: 6 AND A FULL LENGTH CHAIN OF SEQ ID NO: 6 SEQ ID NO: 7, 8 AND 15, OR A FRAGMENT OF THEM; THE CHEMICAL ANTIBODY IS RITUXIMAB. IT ALSO REFERS TO A COMBINATION OF THE CD20 ANTIBODY WITH A DRUG SUCH AS ETANERCEPT, INFLIXIMAB, METOTREXATE, OFATUMUMAB, CYCLOPHOSPHAMIDE, AMONG OTHERS AND TO AN INJECTABLE FORMULATION. SUCH ANTIBODIES ARE USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES, INCLUDING RHEUMATOID ARTHRITIS

PE2008001653A 2007-09-24 2008-09-22 INJECTABLE FORMULATION FOR OCRELIZUMAB (2H7) PE20091078A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97464107P 2007-09-24 2007-09-24
GBGB0718684.4A GB0718684D0 (en) 2007-09-24 2007-09-24 Treatment method

Publications (1)

Publication Number Publication Date
PE20091078A1 true PE20091078A1 (en) 2009-07-23

Family

ID=38670460

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001653A PE20091078A1 (en) 2007-09-24 2008-09-22 INJECTABLE FORMULATION FOR OCRELIZUMAB (2H7)

Country Status (10)

Country Link
EP (1) EP2197916A1 (en)
JP (1) JP2011501734A (en)
CN (1) CN101809036A (en)
AR (1) AR068531A1 (en)
CA (1) CA2700351A1 (en)
CL (1) CL2008002817A1 (en)
GB (1) GB0718684D0 (en)
PE (1) PE20091078A1 (en)
TW (1) TW200918091A (en)
WO (1) WO2009040268A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201809892T4 (en) 2003-11-05 2018-07-23 Roche Glycart Ag Antigen binding molecules with binding affinity to the Fc receptor and enhanced effector function.
AR073295A1 (en) 2008-09-16 2010-10-28 Genentech Inc METHODS TO TREAT PROGRESSIVE MULTIPLE SCLEROSIS. MANUFACTURING ARTICLE.
JP2018529747A (en) * 2015-10-06 2018-10-11 ジェネンテック， インコーポレイテッド Methods for treating multiple sclerosis
TWI747885B (en) * 2016-03-07 2021-12-01 法商賽諾菲生物技術公司 Compositions and methods for treating rheumatoid arthritis
MY202382A (en) * 2017-08-08 2024-04-24 Hoffmann La Roche Obinutuzumab treatment of a dlbcl patient subgroup
JP2022502380A (en) * 2018-09-24 2022-01-11 ヤンセン バイオテツク，インコーポレーテツド Methods of Providing Safe Administration of Anti-CD154 Antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1572744T1 (en) * 2002-12-16 2010-09-30 Genentech Inc Immunoglobulin variants and uses thereof
AU2006204757A1 (en) * 2005-01-13 2006-07-20 Genentech, Inc. Treatment method
AU2006272597A1 (en) * 2005-07-25 2007-02-01 Emergent Product Development Seattle Llc Single dose use of CD20-specific binding molecules
MY149159A (en) * 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage

Also Published As

Publication number Publication date
TW200918091A (en) 2009-05-01
CN101809036A (en) 2010-08-18
WO2009040268A1 (en) 2009-04-02
CL2008002817A1 (en) 2009-10-16
JP2011501734A (en) 2011-01-13
AR068531A1 (en) 2009-11-18
CA2700351A1 (en) 2009-04-02
EP2197916A1 (en) 2010-06-23
GB0718684D0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
PE20091078A1 (en) INJECTABLE FORMULATION FOR OCRELIZUMAB (2H7)
LTPA2022520I1 (en)
CO6260105A2 (en) HUMAN ANTIBODIES AGAINST HUMAN CD20 AND METHOD FOR USE
AR124676A2 (en) PHARMACEUTICAL FORMULATION COMPRISING A BIOPHARMACEUTICAL DRUG
PE20200011A1 (en) ANTI-PEPTIDE BETA AMYLOID N3pGlu ANTIBODIES AND THEIR USES
AR081434A1 (en) ANTIBODY OF THE PEPTIDE RELATED TO THE CALCITONINE GENE (CGRP), PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE OF THE ANTIBODY TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT PAIN OR MIGRANE PAIN AND ANOGEN ANOGEN FRAGMENT
PE20141432A1 (en) NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS
PE20120429A1 (en) MYOSTATIN BINDING PROTEINS
PE20120816A1 (en) COMPOSITIONS INCLUDING DICKKOPF-1 ANTIBODIES
AR072985A1 (en) TREATMENT FOR AN AUTOIMMUNE DISEASE OR INFLAMMATORY DISORDER, PROCEDURE, ANTIBODY, UNION PROTEIN
AR106184A1 (en) PD-1 BINDING PROTEINS AND THEIR METHODS OF USE
PE20110802A1 (en) AN ANTAGONIST ANTIBODY OF PCSK9
PE20200695A1 (en) ANTIBODIES THAT RECOGNIZE TAU
PE20081478A1 (en) CD44 ANTIBODIES
PE20190261A1 (en) ANTIBODIES THAT RECOGNIZE TAU
PE20120205A1 (en) ANTI-TUMOR COMBINATIONS CONTAINING ANTIBODIES THAT SPECIFICALLY RECOGNIZE CD38 AND CITARABIN
ES2572177T3 (en) Human anti-B7RP1 neutralizing antibodies
PE20091197A1 (en) Bv8 ANTAGONISTS AS ANGIOGENESIS INHIBITORS
PE20180249A1 (en) NEUTRALIZING ANTIBODIES ANTI-CCL20
PE20130393A1 (en) ANTIBODIES WITH PH-DEPENDENT ANTIGEN UNION
PE20120431A1 (en) ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER
PE20081171A1 (en) NEW ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER
PE20081264A1 (en) ANTI-NOTCH3 AGONIST ANTIBODIES
PE20121691A1 (en) FORMULATION OF ANTIBODIES AND THERAPEUTIC REGIMES
PE20141045A1 (en) BCMA BINDING PROTEINS (CD269 / TNFRSF17)

Legal Events

Date Code Title Description
FD Application declared void or lapsed